Human TLR10 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB6619
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Western Blot
Cited:
Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # 670719
Product Specifications
Immunogen
E. coli-derived recombinant human TLR10
Asn168-Lys383
Accession # Q9BXR5
Asn168-Lys383
Accession # Q9BXR5
Specificity
Detects human TLR10 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TLR1, 2, 3, 4, 5, 7, 8, 9, recombinant mouse (rm) TLR6, 11, 12, rhIL-1 RI, rhIL-1 RII, rhIL-1 RAcP, rhST2, rhIL-18 R, rhIL-1 Rrp2, rhIL-18 R beta, rhSIGIRR, rhIL-1 RAPL1, rhTIGIRR, rhMD-1, rhMD-2, rhTIRAP, or rmRP105 is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Scientific Data Images for Human TLR10 Antibody
Detection of Human TLR10 by Western Blot.
Western blot shows lysates of Daudi human Burkitt's lymphoma cell line. PVDF Membrane was probed with 2 µg/mL of Human TLR10 Monoclonal Antibody (Catalog # MAB6619) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for TLR10 at approximately 95 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Detection of Human TLR10 by Western Blot
NETs promoted STING upregulation by activating TLR2 signaling. A KEGG analysis identified significantly altered pathways in control and NET-treated HUVECs. B Relative mRNA levels of TLRs in control and NET-treated HUVECs (n = 3). C Western blot images of TLRs expression in control and NET-treated HUVECs. D Representative images of immunofluorescence staining of TLR2 in control and NET-treated HUVECs. Scale bar: 30 μm. The expression of TLR2 was assessed by fluorescence intensity (n = 3). E The cell viability of HUVECs pretreated with C-29 (n = 3). F Relative mRNA levels of TLR2, STING, and TF in HUVECs pretreated with C-29 (n = 3). G Western blot images of STING pathway and TF expression in HUVECs pretreated with C-29. H Relative mRNA levels of STING in HUVECs transfected with LV-NC-RNAi or LV-TLR2-RNAi (n = 3). I Western blot images of TLR2 expression in HUVECs transfected with LV-NC-RNAi or LV-TLR2-RNAi. J Western blot was performed to analyze the levels of STING and TF expression in HUVECs transfected with LV-NC-RNAi or LV-TLR2-RNAi under stimulation of NETs. K Western blot images of TLR2 expression in HUVECs pretreated with DNase I. L Western blot images of TLR2 expression in murine lung tissues treated with DNase I. Each bar represents the mean ± SD. The comparison between the two groups was performed using unpaired t-tests (B, D, and H). Statistical analysis for three or more groups was carried out using 1-way ANOVA (E and F). *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37626060), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Human TLR10 by Western Blot
NETs promoted STING upregulation by activating TLR2 signaling. A KEGG analysis identified significantly altered pathways in control and NET-treated HUVECs. B Relative mRNA levels of TLRs in control and NET-treated HUVECs (n = 3). C Western blot images of TLRs expression in control and NET-treated HUVECs. D Representative images of immunofluorescence staining of TLR2 in control and NET-treated HUVECs. Scale bar: 30 μm. The expression of TLR2 was assessed by fluorescence intensity (n = 3). E The cell viability of HUVECs pretreated with C-29 (n = 3). F Relative mRNA levels of TLR2, STING, and TF in HUVECs pretreated with C-29 (n = 3). G Western blot images of STING pathway and TF expression in HUVECs pretreated with C-29. H Relative mRNA levels of STING in HUVECs transfected with LV-NC-RNAi or LV-TLR2-RNAi (n = 3). I Western blot images of TLR2 expression in HUVECs transfected with LV-NC-RNAi or LV-TLR2-RNAi. J Western blot was performed to analyze the levels of STING and TF expression in HUVECs transfected with LV-NC-RNAi or LV-TLR2-RNAi under stimulation of NETs. K Western blot images of TLR2 expression in HUVECs pretreated with DNase I. L Western blot images of TLR2 expression in murine lung tissues treated with DNase I. Each bar represents the mean ± SD. The comparison between the two groups was performed using unpaired t-tests (B, D, and H). Statistical analysis for three or more groups was carried out using 1-way ANOVA (E and F). *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37626060), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human TLR10 Antibody
Application
Recommended Usage
Western Blot
2 µg/mL
Sample: Daudi human Burkitt's lymphoma cell line
Sample: Daudi human Burkitt's lymphoma cell line
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Sterile PBS to a final concentration of 0.5 mg/mL. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TLR10
Long Name
Toll-like Receptor 10
Alternate Names
CD290
Entrez Gene IDs
81793 (Human)
Gene Symbol
TLR10
UniProt
Additional TLR10 Products
Product Documents for Human TLR10 Antibody
Product Specific Notices for Human TLR10 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...